Alpine Woods Capital Investors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,000
| Closed | -$287K | – | 188 |
|
|
2024
Q1 | $287K | Hold |
4,000
| – | – | 0.06% | 159 |
|
|
2023
Q4 | $286K | Hold |
4,000
| – | – | 0.04% | 153 |
|
|
2023
Q3 | $208K | Hold |
4,000
| – | – | 0.03% | 158 |
|
|
2023
Q2 | $253K | Hold |
4,000
| – | – | 0.04% | 151 |
|
|
2023
Q1 | $217K | Hold |
4,000
| – | – | 0.03% | 169 |
|
|
2022
Q4 | $212K | Sell |
4,000
-500
| -11% | -$25.1K | 0.03% | 175 |
|
|
2022
Q3 | $209K | Sell |
4,500
-200
| -4% | -$10.4K | 0.03% | 189 |
|
|
2022
Q2 | $268K | Hold |
4,700
| – | – | 0.03% | 179 |
|
|
2022
Q1 | $288K | Hold |
4,700
| – | – | 0.03% | 198 |
|
|
2021
Q4 | $246K | Buy |
+4,700
| New | +$197K | 0.02% | 205 |
|
|
2020
Q4 | – | Sell |
-14,200
| Closed | -$364K | – | 248 |
|
|
2020
Q3 | $364K | Sell |
14,200
-1,500
| -10% | -$34.2K | 0.06% | 204 |
|
|
2020
Q2 | $403K | Sell |
15,700
-2,200
| -12% | -$44.5K | 0.08% | 198 |
|
|
2020
Q1 | $275K | Hold |
17,900
| – | – | 0.06% | 217 |
|
|
2019
Q4 | $614K | Hold |
17,900
| – | – | 0.12% | 160 |
|
|
2019
Q3 | $134K | Sell |
17,900
-200
| -1% | -$1.92K | 0.02% | 254 |
|
|
2019
Q2 | $235K | Hold |
18,100
| – | – | 0.05% | 249 |
|
|
2019
Q1 | $220K | Hold |
18,100
| – | – | 0.05% | 235 |
|
|
2018
Q4 | $206K | Sell |
18,100
-2,700
| -13% | -$43.6K | 0.05% | 244 |
|
|
2018
Q3 | $451K | Hold |
20,800
| – | – | 0.09% | 162 |
|
|
2018
Q2 | $368K | Sell |
20,800
-200
| -1% | -$4.06K | 0.08% | 168 |
|
|
2018
Q1 | $442K | Sell |
21,000
-100
| -0.5% | -$1.95K | 0.02% | 318 |
|
|
2017
Q4 | $306K | Sell |
21,100
-70,444
| -77% | -$1.09M | 0.02% | 365 |
|
|
2017
Q3 | $1.45M | Buy |
91,544
+18,000
| +24% | +$264K | 0.07% | 212 |
|
|
2017
Q2 | $913K | Sell |
73,544
-400
| -0.5% | -$4.64K | 0.05% | 256 |
|
|
2017
Q1 | $1.2M | Hold |
73,944
| – | – | 0.06% | 230 |
|
|
2016
Q4 | $1.12M | Buy |
73,944
+3,400
| +5% | +$48K | 0.06% | 227 |
|
|
2016
Q3 | $1.07M | Buy |
70,544
+17,400
| +33% | +$704K | 0.06% | 234 |
|
|
2016
Q2 | $2.06M | Hold |
53,144
| – | – | 0.12% | 166 |
|
|
2016
Q1 | $1.48M | Buy |
53,144
+1,200
| +2% | +$40K | 0.09% | 199 |
|
|
2015
Q4 | $2.79M | Sell |
51,944
-900
| -2% | -$45.4K | 0.15% | 147 |
|
|
2015
Q3 | $2.12M | Buy |
+52,844
| New | +$1.72M | 0.12% | 178 |
|
Other funds holding ITCI
WA
ACA
BG
Alpine Woods Capital Investors's ITCI Position: Q2 2024 in Review
Alpine Woods Capital Investors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 4,000 shares — an estimated $287K sold.
Alpine Woods Capital Investors first reported a position in ITCI in Q3 2015 and held it in 31 quarters. The position peaked at $2.79M in Q4 2015. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.
- Alpine Woods Capital Investors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
- Alpine Woods Capital Investors sold 4,000 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $287K.
- Alpine Woods Capital Investors first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 31 quarters.
- Alpine Woods Capital Investors's Intra-Cellular Therapies Inc. position peaked at $2.79M in Q4 2015.
- 376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.
Based on Alpine Woods Capital Investors's 13F filing for Q2 2024, filed 6 Aug 2024.